CooperCompanies stock trades steadily as contact lens growth supports earnings
Published on 07/25/2026 at 11:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CooperCompanies Inc. (ISIN US21664P1039) stock is backed by steady fundamentals, with the medical device group reporting higher revenue and earnings for fiscal 2024 compared with the prior year as its CooperVision contact lens unit remains the main growth engine.
Revenue up in fiscal 2024
According to the companys information for fiscal 2024, CooperCompanies generated a revenue figure in the billions of US dollars, representing an increase versus fiscal 2023 and underlining continued demand for its ophthalmic and womens health products.
The group reported operating profit and net income for fiscal 2024 that were above the prior year levels, supported by higher sales volumes and a focus on specialty contact lenses as well as fertility and obstetrics offerings.
Management highlighted in its commentary on the fiscal 2024 results that CooperVision delivered solid organic growth across key markets, while CooperSurgical continued to expand its portfolio in fertility and gynecology, contributing to the overall improvement in profitability year on year.
CooperVision drives growth
CooperVision remains the largest segment of CooperCompanies, focusing on soft contact lenses for conditions such as myopia, hyperopia and astigmatism, as well as presbyopia. The segment recorded revenue growth in fiscal 2024 compared with fiscal 2023, reflecting increased adoption of daily disposable lenses and specialty offerings.
Within CooperVision, sales of silicone hydrogel daily disposable lenses increased compared with the prior year period, and the company continued to emphasize toric and multifocal products that address more complex vision needs.
CooperSurgical, which offers products and services in fertility, obstetrics and gynecology, also delivered revenue growth in fiscal 2024, with particular strength in fertility solutions and related consumables.
CooperCompanies fundamentals and filings
Investors who want to explore CooperCompanies in more depth can review regulatory filings and past coverage for additional context on earnings trends and balance sheet metrics.
Contact lens portfolio and innovation
CooperCompanies key product line is its CooperVision range of soft contact lenses, which includes daily disposable and reusable lenses, specialty toric lenses for astigmatism, and multifocal lenses for presbyopia.
In recent reporting periods, the company noted that demand for daily disposable lenses has been rising, and that its expanding portfolio in this category is an important driver of revenue and margin.
CooperSurgical supplements this with products in fertility clinics, obstetrics, and gynecology practices, supporting a diversified revenue base within the broader medical device and health care sector.
CooperCompanies stock and market context
CooperCompanies stock is listed on the New York Stock Exchange, reflecting its status as a US-based medical device firm with international operations in eye care and womens health.
The companys market capitalization stands at several billions of US dollars, placing it among mid to large capitalization health care names with exposure to consumable medical products and elective procedures.
For long term observers, the combination of contact lens growth and womens health expansion provides a framework to analyze CooperCompanies earnings resilience and potential sensitivity to consumer spending and health care utilization trends.
CooperCompanies at a glance
- Company: CooperCompanies Inc.
- ISIN: US21664P1039
- Ticker: NYSE: COO
- Trading venue: NYSE
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
